Latest From Endocyte Inc.
At Novartis’s first R&D day since he took the helm, new CEO Vas Narasimhan told Scrip about how the company plans to build value through its newly acquired breakthrough technologies and what deals it is looking for next.
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions...
The company's $2.1bn acquisition of Endocyte and expansion into radiopharmaceuticals dominated some of the call, but with the launches of drugs like Cosentyx, Kymriah, Kisqali and Aimovig underway, there was a lot for Novartis' management team to address.
Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.
- In Vitro Diagnostics
- Diagnostic Imaging Equipment & Supplies
- Drug Delivery
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Endocyte Inc.
- Senior Management
Michael A Sherman, Pres. & CEO
Michael T Andriole, CFO
Matthew Call, VP, Bus. Dev. & Mktg.
Philip S Low, PhD, CSO
Alison A Armour, MD, CMO
- Contact Info
Phone: (765) 463-7175
3000 Kent Ave.
West Lafayette, IN 47906
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.